Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oxybutynin Clear all
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

NCT00224016
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
6 Years to 15 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
23
States / cities
Little Rock, Arkansas • Orange County, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Sep 5, 2026, 12:49 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.

NCT02176642
View directory record Official record
Conditions
Urinary Urge Incontinence
Interventions
Oxybutynin extended release, Posterior Tibial Nerve Stimulation, Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 4 Interventional Results available

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

NCT04090190
View directory record Official record
Conditions
Urinary Incontinence, Urgency Urinary
Interventions
Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Not applicable Interventional Results available

Enhancing Conservative Treatment for Urge Incontinence

NCT00223821
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Oxybutynin chloride, extended-release, individually-titrated, Behavior Training
Drug · Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
19 Years and older · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

NCT00224029
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin transdermal system
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg

NCT00648843
View directory record Official record
Conditions
Healthy
Interventions
Oxybutynin Chloride Extended-release Tablets 5 mg, Ditropan XL® Tablets 5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

NCT04534491
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin (Oxytrol, BAY839380)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Not applicable Interventional

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

NCT00892450
View directory record Official record
Conditions
Parkinson's Disease, Overactive Bladder
Interventions
Oxybutynin and darifenacin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

NCT00501267
View directory record Official record
Conditions
Overactive Bladder
Interventions
solabegron and oxybutynin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 5, 2026, 12:49 AM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 3 Interventional

Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

NCT03050827
View directory record Official record
Conditions
Diabetic; Neuropathic, Polyneuropathy (Manifestation)
Interventions
3% oxybutynin, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy

NCT01829425
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
Anticholinergic medications, Hypnotherapy
Drug · Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 5, 2026, 12:49 AM EDT
Completed No phase listed Observational

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
Interventions
mirabegron, antimuscarinic medication
Drug
Lead sponsor
Astellas Scientific & Medical Affairs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 4 Interventional Results available

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

NCT01178827
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, oxybutynin IR, oxybutynin IR placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

NCT01557244
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
18
States / cities
Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults

NCT02633371
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Oxybutynin 3% gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 25 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available

A Novel Pharmacological Therapy for Obstructive Sleep Apnea

NCT03919955
View directory record Official record
Conditions
Sleep Apnea
Interventions
Atomoxetine, Oxybutynin, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Oxybutynin Topical Gel on Gastric Emptying

NCT00926926
View directory record Official record
Conditions
Healthy
Interventions
Oxybutynin Chloride Gel, Placebo Gel
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

NCT04600336
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Oxybutynin Chloride, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
103
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea

NCT05944965
View directory record Official record
Conditions
OSA
Interventions
Atomoxetine 80 mg plus Oxybutynin 5 mg, Atomoxetine 80 MG, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects Of Detrol LA On Memory And Cognition In Elderly Population

NCT00411437
View directory record Official record
Conditions
Memory, Cognition
Interventions
Tolterodine ER, Oxybutynin ER
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
65 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tucson, Arizona • Brooksville, Florida • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 5, 2026, 12:49 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea

NCT07577661
View directory record Official record
Conditions
Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions
Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
Other · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Oxybutynin Chloride in Managing Hot Flashes

NCT02961790
View directory record Official record
Conditions
Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ, No Evidence of Disease
Interventions
Oxybutynin Chloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Peoria, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 5, 2026, 12:49 AM EDT
Not listed Phase 1Phase 2 Interventional

Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy

NCT05550246
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Atomoxetine, Oxybutynin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 5, 2026, 12:49 AM EDT